Rhabdomyolysis in a patient treated with linezolid for extensively drug-resistant tuberculosis

Clinical Infectious Diseases

Volumn 54, Issue 11, 2012, Pages 1624-1627

  Carroll, Matthew W ^a   Choi, Hongjo ^b   Min, Seonyeong ^b   Hwang, Soohee ^c   Park, Hyeeun ^b   Song, Taeksun ^b   Park, Yumi ^b   Jeon, Han Seung ^b   Goldfeder, Lisa C ^a   Via, Laura E ^a   Lebron, Janette ^a   Jin, Boyoung ^b   Cai, Ying ^a   Barry, Clifton E ^a,b   Lee, Myungsun ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b International Tuberculosis Research Center   (South Korea)

^c Masan National Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; CLARITHROMYCIN; CREATINE KINASE; CYCLOSERINE; LEVOFLOXACIN; LINEZOLID; PROTIONAMIDE;

ADULT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; CREATINE KINASE BLOOD LEVEL; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG WITHDRAWAL; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; MALE; MITOCHONDRION; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RHABDOMYOLYSIS; SIDE EFFECT; SKELETAL MUSCLE; SPUTUM SMEAR; TUBERCULOSIS;

ACETAMIDES; ADULT; ANTITUBERCULAR AGENTS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; MALE; OXAZOLIDINONES; RHABDOMYOLYSIS;

EID: 84861033760     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis293     Document Type: Article

References (15)

1. Condos R, Hadgiangelis N, Leibert E, Jacquette G, Harkin T, Rom WN. Case series report of a linezolid-containing regimen for extensively drug-resistant tuberculosis. Chest 2008; 134:187-92.
2. Yew WW, Leung CC. Antituberculosis drugs and hepatotoxicity. Respirology 2006; 11:699-707.
3. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30:239-45.
4. Allison GW, Perla RJ, Belliveau PP, Angelis SM. Elevated creatine phosphokinase levels associated with linezolid therapy. Am J Health Syst Pharm 2009; 66:1097-100.
5. Hsiao SH, Chang CM, Tsao CJ, Lee YY, Hsu MY, Wu TJ. Acute rhab-domyolysis associated with ofloxacin/levofloxacin therapy. Ann Phar-macother 2005; 39:146-9.
6. McKee EE, Ferguson M, Bentley AT, Marks TA. Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones. Antimi-crob Agents Chemother 2006; 50:2042-9.
7. Bolhuis MS, van Altena R, Uges DR, van der Werf TS, Kosterink JG, Alffenaar JW. Clarithromycin significantly increases linezolid serum concentrations. Antimicrob Agents Chemother 2010; 54:5418-9.
8. Brener ZZ, Bilik I, Khorets B, Winchester JF, Bergman M. Rhabdo-myolysis following clarithromycin monotherapy. Am J Med Sci 2009; 338:78.
9. Packer S, Berman SA. Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid. Am J Psychiatry 2007; 164: 346-7.
10. Mah JH, Kim YJ, No HK, Hwang HJ. Determination of biogenic amines in kimchi, Korean traditional fermented vegetable products. Food Sci Biotechnol 2004; 13:826-9.
11. Kompare M, Rizzo WB. Mitochondrial fatty-acid oxidation disorders. Semin Pediatr Neurol 2008; 15:140-9.
12. Scruggs ER, Naylor A.J.D. Mechanisms of zidovudine-induced mito-chondrial toxicity and myopathy. Pharmacology 2008; 82:83-8.
13. Nagiec EE, Wu LP, Swaney SM, et al. Oxazolidinones inhibit cellular proliferation via inhibition of mitochondrial protein synthesis. Anti-microb Agents Chemother 2005; 49:3896-902.
14. Beekmann SE, Gilbert DN, Polgreen PM. Toxicity of extended courses of linezolid: results of an Infectious Diseases Society of America Emerging Infections Network survey. Diagn Microbiol Infect Dis 2008; 62:407-10.
15. Garrabou G, Soriano A, Lopez S, et al. Reversible inhibition of mito-chondrial protein synthesis during linezolid-related hyperlactatemia. Antimicrob Agents Chemother 2007; 51:962-7.